If future research confirms these results in humans, low-dose semaglutide may be a treatment option for people with heart failure who do not need to lose weight or who cannot tolerate the standard doses of semaglutide
Similarly to GLP-1 injections, many patients will choose to continue treatment long-term for the best results
Mazdutides reported weight-loss figures (up to 16.65% at 60 weeks) are in a broadly similar range to semaglutides pivotal trial results (around 15% at 68 weeks), though the two compounds havent been compared in the same trial with matched populations
Semaglutide, available as Ozempic (for diabetes) and Wegovy (for weight loss), is more widely distributed and often easier to access, both in the US and internationally
And it didnt find a difference, albeit the study was small, I think it was twenty four patients
The liver synthesizes most of the clotting factors in your blood